Hepatitis C treatments - Trio will present rates of treatment denials; Medicare, Medicaid and private insurers

MARCH 9, 2017
Coverage Denials Eyed in HCV Rx Nonstarts
By Gina Shaw
Coverage denials by payors are the main factor in a dramatic rise in failure to start hepatitis C drug treatment over the past three years, according to new data released March 8 by Trio Health, which has collected real-world evidence on 15,000 HCV patients since the launch of the direct-acting antiviral agents (DAAs) in 2014.

Trio Health to Present Data Showing Patient Demand for Curative Hepatitis C Therapies Including Denial Rates by Payer Type

Interim findings from 15,000-patient study to be reviewed on webcast on March 8, 2017

LA JOLLA, CA--(Marketwired - March 06, 2017) - Trio Health today announced it will unveil interim results from its study evaluating real-world demand for curative hepatitis C treatments. Using its first-of-a-kind platform designed to track drug prescriptions, starts and denials in real time -- from a doctor's prescription to the pharmacy to payers -- Trio will present rates of treatment denials based on payer type, including Medicare, Medicaid and private insurers. The study includes over 15,000 patients nationwide.

The data will be presented at a meeting in New York City organized by The Trout Group and webcast beginning at 12:15 p.m. EST on March 8, 2017. To hear the webcast, please go to at http://triohealth.troutgroup.com.

About Trio Health
Trio Health's mission is to improve the quality of care in patient outcomes through coordinating the efforts of all patient care stakeholders. Their first-of-its-kind Innervation platform tracks patients throughout the course of their treatment, giving pharmaceutical/biotechnology companies, specialty pharmacies and physicians access to information and opportunities that simply don't exist anywhere else. Learn more at www.triohealth.com.